RT Journal Article SR Electronic T1 Livin/melanoma inhibitor of apoptosis protein as a potential therapeutic target for the treatment of malignancy JF Molecular Cancer Therapeutics JO Mol Cancer Ther FD American Association for Cancer Research SP 24 OP 30 DO 10.1158/1535-7163.MCT-06-0443 VO 6 IS 1 A1 Chang, Hong A1 Schimmer, Aaron D. YR 2007 UL http://mct.aacrjournals.org/content/6/1/24.abstract AB Livin, also called melanoma inhibitor of apoptosis protein (IAP) or kidney IAP, is a member of the IAP family of caspase inhibitors that selectively binds the endogenous IAP antagonist SMAC and caspase-3, caspase-7, and caspase-9. As such, Livin inhibits apoptosis, and its overexpression renders malignant cells resistant to chemotherapy. Therefore, inhibitors of Livin could be useful adjuncts to chemotherapy in the treatment of malignancies. This review will discuss Livin as a potential therapeutic target and strategies for its inhibition, including antisense oligonucleotides, small-molecule inhibitors, and immune-mediated approaches. [Mol Cancer Ther 2007;6(1):24–30]